- Positive New Data from Phase 1/2 Trial of AT-01 Presented at 2022 American College of Cardiology Annual Scientific Session
- Fully Automated 3D Segmentation and Quantitation of the Amyloidophilic Radiotracer Iodine Evuzamitide (124i-P5+14, AT-01) in the Heart of Patients with Systemic Amyloidosis and Healthy Subjects
- Detection of Cardiac Amyloidosis in Patients with Systemic AL and ATTR Amyloidosis Using Iodine Evuzamitide PET/CT Imaging and the Correlation with Serum NT-proBNP
- Attralus Appoints James Testa as Vice President of Finance
- Attralus is Developing a New Treatment for Systemic Amyloidosis
No comments to show.